Be the first person to write a business review for Genencor International, Inc.

Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are licensed to market products based on the Company’s technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Daclizumab, Ranibizumab, Etanercept, Adalimumab and Infliximab. In March 2009, Roche Holding Ltd. completed the acquisition of Genentech.

Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.

Genetix Group plc, along with its subsidiaries, is engaged in the design, development, manufacture and marketing of automated systems, services and consumables for cell biology, cytogenetics, pathology, proteomic and genomic research worldwide. The biopharmaceutical family of products include the ClonePixFL and associated reagents, which are used to identify the antibody clones that form the basis of pharmaceutical drugs. The ClonePix FL is also used to identify high-yielding cell lines for a customer’s production process. Its Cytovision systems are used worldwide for both pre and post natal genetic testing, and identifying certain forms of cancer, such as leukemia. Its Ariol system is used to image tissue samples from patients. Its wholly owned subsidiaries include Genetix Limited, Genescreen Limited, Genpak Limited, Genetix GmbH and Genetix KK. In April 2009, the Company acquired SlidePath Limited. In January 2010, Danaher Corporation acquired 97% interest in the Company.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Genitope is a drug development company in arrested development. It had hoped to find new ways to fight cancer with old weapons, but now it is just hoping to find a future. The company was researching immunotherapy treatments for cancer, using the body's own immune system to fight tumors. Genitope's leading drug candidate, MyVax, was a patient-specific immunotherapy that would specify the genetic makeup of the tumor, activate the patient's immune system to attack it, and cause no damage to cells other than the tumor. However, the drug did not do well in early clinical trials, and when the FDA requested additional trials for further review, Genitope chose to scrap the whole program.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.